What will the new year have in store for stem cells? 2016 promises to have many striking stem cell developments. Below are my top 20 stem cell predictions for what is to come this year in no particular order. Share your stem cell tea leaves in the comments please. Another stem cell biotech acquisition by pharma (recall Ocata (almost now finally sold) & CDI in 2015). Charging patients for clinical trial participation, particularly in Japan due to the new policy and here in the US …Read More
What were the top 10 stem cell stories of the year? What were the biggest news and science headlines in the stem cell field in 2015, whether good or bad? Below are mine. What are your top 10 stem cell stories of the past year? Let us know in the comments. Organoids explode. Stem cell-based mini-organs (organoids) have exploded in terms of impact in the last couple years. 2015 had many examples of these super cool human organs in a dish made from stem …Read More
Money plays a major role in the arena of stem cells, cell therapy, and regenerative medicine. The financial side of this cutting-edge field ranges from grants to private investors to publicly traded stocks. One could argue that the flow of total investment going into this area has a direct and tangible impact on how rapidly and effectively the research moves forward. In the specific area of publicly traded companies working in stem cells, cell therapy, and regenerative medicine, what’s the investment outlook for the coming …Read More
It seems like Fridays are always a good time for reflection. It’s not like the scientist’s week ends on Friday sad to say, but still at least we can pause momentarily TGIF style and reflect on the maelstrom that is our lives, while cracking open another diet Coke or pouring another cup of coffee. This week was a great one for getting into some intense discussions with other scientists both in person and electronically. CRISPR the talk of the biology town. Everyone is talking …Read More
The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did its IPO with an initial offering of about $46 million. Fujifilm reportedly has a multibillion-dollar war chest for buying into the life sciences sector and a growing interest in regenerative …Read More
What is the most exciting, important, promising, all-around awesome stem cell biotech of 2014? Vote and tell us why in the comments.